Lysine-specific histone demethylase 1 inhibition enhances robust fetal hemoglobin induction in human β0-thalassemia/hemoglobin E erythroid cells

Induction of fetal hemoglobin (HbF) ameliorates the clinical severity of beta-thalassemias. Histone methyltransferase LSD1 enzyme removes methyl groups from the activating chromatin mark histone 3 lysine 4 at silenced genes, including the gamma-globin genes. LSD1 inhibitor RN-1 induces HbF levels in cultured human erythroid cells. Here, the HbF-inducing activity of RN-1 was investigated in erythroid progenitor cells derived from beta(0)-thalassemia/ hemoglobin E (HbE) patients. The significant and reproducible increases in gamma-globin transcript and HbF expression upon RN-1 treatment were demonstrated in erythroid cells with divergent HbF baseline levels, the average of HbF induction was 17.7 +/- 0.8%. RN-1 at low concentration did not affect viability and proliferation of erythroid cells, but decreases in cell number were observed in cells treated with RN- 1 at high concentration. Delayed terminal erythroid differentiation was revealed in beta(0)-thalassemia/HbE erythroid cells treated with RN-1 as similar to other compounds that target LSD1 activity. Downregulation of repressors of gamma-globin expression; NCOR1 and SOX6, was observed in RN-1 treatment. These findings provide proof of the concept that LSD1 epigenetic enzyme is a potential therapeutic target for beta(0)-thalassernia/HbE patients.

Automated summary

The use of LSD1 inhibitor RN-1 significantly increases gamma-globin transcript and HbF expression levels in erythroid cells derived from beta(0)-thalassemia/HbE patients, without affecting cell viability and proliferation at low concentration, but leading to decreased cell numbers at high concentration.